XNCR Xencor Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1326732 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY19.8%
TTM net income YoY15.1%
TTM EPS YoY9.8%
Revenue 3-yr CAGR11.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-72.7%
Net margin-58.8%
FCF margin-88.0%
EBITDA margin-67.9%
Returns
ROE-19.9%
ROA-14.4%
ROIC (approx.)-17.4%
Asset turnover0.24x
Leverage & solvency
Liabilities / assets27.3%
Debt / equity0.17x
Current ratio6.54x
Interest coverage-6.19x
Cash quality & payout
Operating cash flow / net income1.46x
Accruals ratio6.6%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $125.58M | $110.49M | $174.62M | $164.58M | $275.11M |
| R&D expense | $239.43M | $227.69M | $253.60M | $199.56M | $192.51M |
| SG&A expense | $63.64M | $61.22M | $53.38M | $47.49M | $38.84M |
| Operating income | -$177.50M | -$178.41M | -$132.36M | -$82.47M | $43.77M |
| Interest expense | $31.93M | $36.64M | $6.18M | $13,000 | $13,000 |
| Pretax income | -$89.63M | -$234.92M | -$119.63M | -$54.51M | $82.63M |
| Income tax | $2.50M | $1.62M | $13.66M | $673,000 | $0 |
| Net income | -$91.92M | -$232.62M | -$133.13M | -$55.18M | $82.63M |
| EBITDA | -$166.99M | -$166.30M | -$120.86M | -$73.67M | $51.26M |
| EPS (basic) | -1.24 | -3.58 | -2.20 | -0.93 | 1.42 |
| EPS (diluted) | -1.24 | -3.58 | -2.20 | -0.93 | 1.37 |
| Weighted avg. shares (diluted) | 74.24M | 65.04M | 60.50M | 59.65M | 60.50M |
| Banking | |||||
| Net interest income | — | $31.93M | $19.33M | $4.83M | $849,000 |
| Balance sheet | |||||
| Cash & equivalents | $54.07M | $41.26M | $54.17M | $53.94M | $143.48M |
| Receivables | $29.30M | $60.85M | $23.74M | $29.00M | $66.38M |
| Current assets | $599.82M | $577.60M | $635.60M | $675.34M | $424.37M |
| PP&E, net | $53.31M | $59.80M | $66.12M | $59.18M | $28.24M |
| Intangibles | $8.38M | $18.48M | $18.66M | $18.50M | $16.49M |
| Total assets | $875.50M | $951.95M | $965.13M | $846.27M | $838.21M |
| Current liabilities | $95.91M | $87.43M | $73.92M | $63.84M | $70.74M |
| Short-term debt | $43.27M | $48.45M | $27.71M | $0 | — |
| Long-term debt | $76.48M | $115.16M | $161.77M | $0 | — |
| Total debt | $119.75M | $163.61M | $189.48M | $0 | — |
| Total liabilities | $239.91M | $277.92M | $303.05M | $118.77M | $104.71M |
| Shareholders' equity | $635.59M | $677.61M | $661.75M | $727.50M | $733.50M |
| Net debt | $65.68M | $122.34M | $135.31M | -$53.94M | — |
| Shares outstanding | 71.87M | 70.26M | 61.00M | 60.00M | 59.36M |
| Cash flow statement | |||||
| Operating cash flow | -$135.12M | -$202.19M | -$77.93M | $24.48M | -$16.85M |
| Capital expenditure | $3.15M | $6.10M | $18.45M | $38.49M | $13.30M |
| Free cash flow | -$138.27M | -$208.28M | -$96.37M | -$14.01M | -$30.15M |
| Investing cash flow | $139.99M | -$7.87M | -$111.06M | -$119.72M | -$46.25M |
| Financing cash flow | $8.23M | $197.15M | $189.22M | $5.70M | $43.04M |
| Depreciation & amortization | $10.51M | $12.11M | $11.50M | $8.80M | $7.49M |
| Stock-based compensation | $43.23M | $53.28M | $53.76M | $48.91M | $36.98M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.